ArticleCancer2022
Multicancer early detection test: Preclinical, translational, and clinical evidence-generation plan and provocative questions.
Article in Cancer, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed.
- Beyond the Needle: Is Liquid Biopsy the Future of Veterinary Medicine?International journal of molecular sciences · 2026Review
- Increasing power and robustness in screening trials by testing stored specimens in the control arm.BMC medical research methodology · 2026Article
- Benchmarking reliability and calibration of LLMs for multi-cancer early detection test communication.JAMIA open · 2026Article
- Measuring and defining screening benefit in a new era of cancer early detection.Journal of the National Cancer Institute · 2026Article
- Early Cancer Detection: What's Going on and What's Next.MedComm · 2026Review
- Potential Economic Value of Multi-cancer Early Detection Testing Under Differential Cost Trends for Cancer Screening and Management.PharmacoEconomics - open · 2026Article
- Impact of Population Cancer Risk on the Cost-effectiveness of Multicancer Early Detection Testing in the United States.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2025Article
- Design of randomized controlled trials to estimate cancer-mortality reductions from multicancer detection screening.Journal of the National Cancer Institute · 2025Article
- Efficient risk-based collection of biospecimens in cohort studies: designing a prospective study of diagnostic performance for multicancer detection tests.American journal of epidemiology · 2025Article
- Multiomics biomarkers were not superior to clinical variables for pan-cancer screening.Communications medicine · 2024Article
- Increasing power in screening trials by testing control-arm specimens: application to multicancer detection screening.Journal of the National Cancer Institute · 2024Article
- Primary care physicians and laypersons' perceptions of multicancer detection clinical trial designs.JNCI cancer spectrum · 2024Article
- Lexicon for blood-based early detection and screening: BLOODPAC consensus document.Clinical and translational science · 2024Article
- Increasing power in screening trials by testing control-arm specimens: application to multicancer detection screening.Journal of the National Cancer Institute · 2024Article
- Considerations for using potential surrogate endpoints in cancer screening trials.The Lancet. Oncology · 2024Review
- An Exploratory Analysis of the Cost-Effectiveness of a Multi-cancer Early Detection Blood Test Compared with Standard of Care Screening in Ontario, Canada.PharmacoEconomics · 2024Article
- Circulating tumour cells for early detection of clinically relevant cancer.Nature reviews. Clinical oncology · 2023Review
- Article
- Multidrug Resistance in Cancer Cells: Focus on a Possible Strategy Plan to Address Colon Carcinoma Cells.Life (Basel, Switzerland) · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Minimally invasive molecular biomarkers have been applied to the early detection of multiple cancers in large scale case-control and cohort studies. These demonstrations of feasibility herald the potential for permanent transformation of current cancer screening paradigms. This commentary discusses the major opportunities and challenges facing the preclinical development and clinical validation of multicancer early detection test strategies. From a diverse set of early detection research perspectives, the authors recommend specific approaches and highlight important questions for future investigation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.